CO6321241A2 - Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) - Google Patents

Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)

Info

Publication number
CO6321241A2
CO6321241A2 CO10057589A CO10057589A CO6321241A2 CO 6321241 A2 CO6321241 A2 CO 6321241A2 CO 10057589 A CO10057589 A CO 10057589A CO 10057589 A CO10057589 A CO 10057589A CO 6321241 A2 CO6321241 A2 CO 6321241A2
Authority
CO
Colombia
Prior art keywords
activity
ksp
quinesina
tiadiazol
espiro
Prior art date
Application number
CO10057589A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Vitharana
Angie Angeles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40220231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6321241(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6321241A2 publication Critical patent/CO6321241A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los compuestos de Fórmula (I), a continuación, (donde X, R1, R2, R3, p, E, el anillo A, y el anillo B son como se definieron en la presente). La presente invención además se refiere a las composiciones (que incluyen composiciones aceptables para uso farmacéutico) que comprenden estos compuestos, solos y en combinación con uno o más agentes terapéuticos adicionales, y a métodos para su uso en la inhibición de la actividad de la quinesina KSP, y para tratar enfermedades proliferativas celulares o trastornos asociados con la actividad de quinesina KSP.Fórmula I
CO10057589A 2007-10-19 2010-05-13 Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) CO6321241A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98128807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6321241A2 true CO6321241A2 (es) 2011-09-20

Family

ID=40220231

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10057589A CO6321241A2 (es) 2007-10-19 2010-05-13 Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)

Country Status (19)

Country Link
US (1) US8796460B2 (es)
EP (1) EP2220061B1 (es)
JP (1) JP5455915B2 (es)
KR (1) KR20100072267A (es)
CN (2) CN101903365B (es)
AR (1) AR068888A1 (es)
AU (1) AU2008312401C1 (es)
BR (1) BRPI0818605A2 (es)
CA (1) CA2702922C (es)
CL (1) CL2008003063A1 (es)
CO (1) CO6321241A2 (es)
ES (1) ES2565983T3 (es)
IL (1) IL205184A0 (es)
MX (1) MX2010004312A (es)
PE (1) PE20091349A1 (es)
RU (1) RU2010119635A (es)
TW (1) TW200934785A (es)
WO (1) WO2009052288A1 (es)
ZA (1) ZA201002701B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
ES2524910T3 (es) 2007-10-19 2014-12-15 Boehringer Ingelheim International Gmbh Piperidino-dihidrotienopirimidinas sustituidas
KR20100075930A (ko) 2007-10-19 2010-07-05 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘
JP5563466B2 (ja) 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
EP2430030A1 (en) * 2009-05-13 2012-03-21 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
JP2013525290A (ja) * 2010-04-15 2013-06-20 ノバルティス アーゲー Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
EP2582682B1 (en) 2010-06-17 2015-01-14 Cytokinetics, Inc. Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9598441B2 (en) 2011-08-30 2017-03-21 Wayne State University Therapeutic compounds and methods
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
CN111529525A (zh) * 2020-05-15 2020-08-14 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂用于治疗胆管癌的用途
CN111358786A (zh) * 2020-05-15 2020-07-03 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂在治疗胆管癌方面的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1847534E (pt) 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2508956A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003297230B2 (en) 2002-12-20 2009-11-26 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
WO2006018628A1 (en) 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
WO2004087050A2 (en) 2003-03-28 2004-10-14 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1616866B1 (en) 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
ATE426605T1 (de) * 2003-06-12 2009-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
AU2004248160B2 (en) 2003-06-12 2010-05-27 Merck Sharp & Dohme Corp. Prodrugs of mitotic kinesin inhibitors
WO2005018638A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2534729A1 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2004266629B2 (en) 2003-08-15 2009-11-26 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
ES2319429T3 (es) 2003-08-15 2009-05-07 MERCK & CO., INC. Inhibidores de cinesina mitotica.
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
US20070112044A1 (en) 2003-10-10 2007-05-17 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
AU2004305069C1 (en) * 2003-12-19 2010-07-29 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2560213A1 (en) 2004-03-22 2005-10-06 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2005236066A1 (en) 2004-04-19 2005-11-03 Merck & Co., Inc. A process for the preparation of 2,2-disubstituted pyrroles
DE102004021637A1 (de) 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
DE102004031656A1 (de) 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
CN1980662A (zh) 2004-07-01 2007-06-13 默克公司 有丝分裂驱动蛋白抑制剂
CN1980911A (zh) 2004-07-01 2007-06-13 默克公司 有丝分裂驱动蛋白抑制剂
RU2007103816A (ru) 2004-07-01 2008-08-10 Мерк энд Ко., Инк. (US) Ингибиторы митотического кинезина
US7718687B2 (en) 2004-07-01 2010-05-18 Merck Sharp & Dohme Corp., Prodrugs of mitotic kinesin inhibitors
JP2008506759A (ja) 2004-07-22 2008-03-06 アストラゼネカ アクチボラグ 癌の処置および予防に有用な縮合ピリミドン類
WO2006023083A1 (en) 2004-08-12 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2576057A1 (en) 2004-08-18 2006-03-23 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20070046175A (ko) 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
CN101076335A (zh) 2004-08-18 2007-11-21 默克公司 有丝分裂驱动蛋白抑制剂
EP1791969A4 (en) 2004-09-13 2008-07-02 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US20080045492A1 (en) 2004-12-21 2008-02-21 Coleman Paul J Mitotic Kinesin Inhibitors
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors
DE102005010000A1 (de) 2005-03-04 2006-09-07 Merck Patent Gmbh Indane
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
MX2007010973A (es) 2005-03-09 2007-09-19 Schering Corp Compuestos para inhibir la actividad de cinesina de ksp.
KR20070113267A (ko) 2005-03-09 2007-11-28 쉐링 코포레이션 Ｋｓｐ 키네신 활성 억제용 화합물
CN101137372A (zh) 2005-03-16 2008-03-05 默克公司 有丝分裂驱动蛋白抑制剂
WO2006101761A2 (en) 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2008150291A (ja) 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
WO2006101103A1 (ja) 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. 造血器腫瘍治療剤
JP2008137893A (ja) 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
WO2006101102A1 (ja) 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. 固形腫瘍治療剤
CN101155583B (zh) 2005-04-07 2011-01-19 默沙东公司 有丝分裂驱动蛋白的抑制剂
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
DE102005027169A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
JPWO2006137490A1 (ja) 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
EP2032584A2 (en) 2006-06-09 2009-03-11 Wyeth Thiadiazole compounds and methods of use thereof
CN101553476A (zh) 2006-10-03 2009-10-07 阵列生物制药公司 作为有丝分裂驱动蛋白抑制剂的二唑和噻二唑衍生物及其使用方法
CA2702985A1 (en) * 2007-11-07 2009-05-14 Schering Corporation Compounds for inhibiting ksp kinesin activity
JP2011503077A (ja) 2007-11-09 2011-01-27 シェーリング コーポレイション Ｋｓｐキネシン活性を阻害するための化合物
JP2011503076A (ja) * 2007-11-09 2011-01-27 シェーリング コーポレイション Ｋｓｐキネシン活性を阻害するための化合物
EP2430030A1 (en) * 2009-05-13 2012-03-21 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors

Also Published As

Publication number Publication date
JP5455915B2 (ja) 2014-03-26
AU2008312401C1 (en) 2014-07-10
KR20100072267A (ko) 2010-06-30
CN103694258B (zh) 2016-01-13
US20110123435A1 (en) 2011-05-26
AU2008312401A1 (en) 2009-04-23
EP2220061B1 (en) 2016-02-17
MX2010004312A (es) 2010-07-05
WO2009052288A1 (en) 2009-04-23
EP2220061A1 (en) 2010-08-25
PE20091349A1 (es) 2009-09-07
CA2702922A1 (en) 2009-04-23
AR068888A1 (es) 2009-12-16
AU2008312401B2 (en) 2014-03-06
CN103694258A (zh) 2014-04-02
CA2702922C (en) 2018-01-16
IL205184A0 (en) 2010-11-30
ES2565983T3 (es) 2016-04-08
CL2008003063A1 (es) 2010-01-04
TW200934785A (en) 2009-08-16
BRPI0818605A2 (pt) 2015-04-22
US8796460B2 (en) 2014-08-05
CN101903365B (zh) 2014-02-05
RU2010119635A (ru) 2011-11-27
JP2011500714A (ja) 2011-01-06
CN101903365A (zh) 2010-12-01
ZA201002701B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP066717A (es) Compuestos de quinolina sustituidos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY28144A1 (es) Agentes terapéuticos
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.

Legal Events

Date Code Title Description
FA Application withdrawn